

Supplementary Table 4. Univariable analysis for event-free survival, progression-free survival, and overall survival in the study cohort

Variable	No. of patients (%)	Event-free survival		Progression-free survival		Overall survival	
		HR (95% CI)	p value	HR (95% CI)	p value	HR (95% CI)	p value
Age, yr			0.002		0.005		< 0.001
≤ 70	74 (29.7)	1		1		1	
70–80	141 (56.6)	1.67 (1.09–2.56)		1.68 (1.09–2.59)		1.96 (1.22–3.14)	
> 80	34 (13.7)	2.62 (1.51–4.55)		2.48 (1.41–4.35)		3.43 (1.90–6.21)	
Sex							
Female	125 (52.2)	1		1		1	
Male	124 (49.8)	0.95 (0.67–1.34)	0.757	0.96 (0.67–1.35)	0.803	1.03 (0.71–1.49)	0.851
Ann Arbor stage							
I–II	109 (43.8)	1		1		1	
III–IV	140 (56.2)	2.77 (1.88–4.08)	< 0.001	3.04 (2.05–4.52)	< 0.001	2.54 (1.69–3.81)	< 0.001
ECOG PS							
0–1	195 (78.3)	1		1		1	
2–4	54 (21.7)	2.80 (1.93–4.06)	< 0.001	3.02 (2.07–4.40)	< 0.001	2.76 (1.87–4.08)	< 0.001
B symptoms							
Absence	203 (81.5)	1		1		1	
Presence	46 (18.5)	2.79 (1.88–4.12)	< 0.001	2.83 (1.90–4.21)	< 0.001	2.43 (1.60–3.70)	< 0.001
Serum LDH level							
Normal	103 (41.0)	1		1		1	
Elevated	147 (59.0)	3.44 (2.28–5.19)	< 0.001	3.46 (2.27–5.24)	< 0.001	3.03 (2.13–5.11)	< 0.001
Extranodal disease							
≤ 1	179 (71.9)	1		1		1	
> 1	70 (28.1)	3.08 (2.16–4.38)	< 0.001	3.34 (2.33–4.79)	< 0.001	2.91 (2.00–4.22)	< 0.001
Bulky disease							
No	227 (91.2)	1		1		1	
Yes	22 (8.8)	1.36 (0.78–2.37)	0.278	1.49 (0.85–2.60)	0.158	1.52 (0.85–2.72)	0.153
Hemoglobin level, g/dL							
≥ 12.0	111 (44.6)	1		1		1	
< 12.0	138 (55.4)	1.99 (1.38–2.88)	< 0.001	2.04 (1.41–2.95)	< 0.001	2.05 (1.39–3.02)	< 0.001
Serum albumin level, g/dL							
≥ 3.5	170 (68.3)	1		1		1	
< 3.5	79 (31.7)	2.64 (1.87–3.74)	< 0.001	2.26 (1.59–3.22)	< 0.001	2.10 (1.45–3.05)	< 0.001
Age-adjusted IPI			< 0.001		< 0.001		< 0.001
Low	65 (24.9)	1		1		1	
Low-intermediate	68 (27.3)	1.74 (0.90–3.36)		1.46 (0.74–2.87)		1.47 (0.73–2.95)	
High-intermediate	84 (33.7)	5.58 (3.12–9.96)		5.93 (3.31–10.63)		5.08 (2.77–9.31)	
High	35 (14.1)	7.60 (3.99–14.49)		7.86 (4.10–15.07)		6.22 (3.18–12.15)	
ADL							
≥ 5	179 (71.9)	1		1		1	
< 5	70 (28.1)	3.38 (2.37–4.82)	< 0.001	3.65 (2.54–5.24)	< 0.001	4.22 (2.88–6.18)	< 0.001

Supplementary Table 4. Continued

Variable	No. of pa- tients (%)	Event-free survival		Progression-free survival		Overall survival	
		HR (95% CI)	<i>p</i> value	HR (95% CI)	<i>p</i> value	HR (95% CI)	<i>p</i> value
IADL							
≥ 7	165 (66.3)	1		1		1	
< 7	84 (33.7)	3.84 (2.70–5.47)	< 0.001	3.64 (2.55–5.20)	< 0.001	4.18 (2.86–6.11)	< 0.001
CCI							
< 2	204 (81.9)	1		1		1	
≥ 2	45 (18.1)	1.95 (1.32–2.89)	0.001	1.85 (1.24–2.76)	0.002	2.01 (1.33–3.03)	0.001

HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; IPI, International Prognostic Index; ADL, Activities of Daily Living; IADL, Instrumental Activities of Daily Living; CCI, Charlson's Comorbidity Index.